GLP-1 receptor agonist (oral tablet)
Oral Semaglutide
The Rybelsus and Ozempic tablet label gives semaglutide's elimination half-life as approximately one week; the app lists 161 hours, about 6.7 days.1
Oral Semaglutide after one dose: 50% at ~161 h, 25% at 322 h, 12.5% at 483 h.
Drawn from the half-life in the app's model, ~161 h. The model's figures
- Compound
- Oral Semaglutide
- Symbol
- RYB
- Family
- GLP-1 and incretin
- Parts
- 14
- References
- 13
- Checked
- Last reviewed . Sources are listed below.
Overview
Oral semaglutide is the once-daily tablet form of semaglutide, a GLP-1 receptor agonist made by Novo Nordisk, sold in the United States as Rybelsus, Ozempic tablets and Wegovy tablets.1,2 The tablet is co-formulated with the absorption enhancer salcaprozate sodium (SNAC).1 The US label for Rybelsus and Ozempic tablets lists two uses in adults with type 2 diabetes mellitus: glycemic control as an adjunct to diet and exercise, and reducing the risk of major adverse cardiovascular events in those at high risk for these events.1 The Wegovy label lists the tablets, in combination with a reduced calorie diet and increased physical activity, for reducing cardiovascular risk in adults with established cardiovascular disease and either obesity or overweight, and for reducing excess body weight and maintaining weight reduction long term in adults with obesity, or with overweight and at least one weight-related comorbid condition.2 The European Medicines Agency's product information for Rybelsus gives 03 April 2020 as the date of first authorisation.3 The app grades the evidence for oral semaglutide as strong, and OASIS 4, PIONEER 6, SOUL and OASIS 1, described below, were each funded by Novo Nordisk.4,5,6,7
How it works
Sources in this part
The Rybelsus and Ozempic tablet label describes semaglutide as "a GLP-1 analogue with 94% sequence homology to human GLP-1".1 It "acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1".1 The label states that semaglutide lowers blood glucose "through a mechanism where it stimulates insulin secretion and lowers glucagon secretion, both in a glucose-dependent manner", and that the mechanism "also involves a minor delay in gastric emptying in the early postprandial phase".1 The label's pharmacodynamic measurements were made in patients with type 2 diabetes who received once-weekly subcutaneous injections, not tablets.1 For the tablet, the label states that SNAC "facilitates the absorption of semaglutide after oral administration" and that absorption "predominantly occurs in the stomach".1
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~161 h
- Bioavailability
- 1%
- Typical dose
- 1.5–25 mg/day
- Route
- Oral
- Time to peak
- ~1 h
Sources in this part
The second column of the table holds the app's own figures, shown beside what the labels report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~161 h (about 6.7 days) | Elimination half-life of approximately one week, with an absolute clearance of approximately 0.04 L/hour in patients with type 2 diabetes, on the Rybelsus and Ozempic tablet label; elimination half-life of approximately 1 week, with semaglutide present in the circulation for about 5 to 7 weeks after the last oral dose of 25 mg, on the Wegovy label1,2 |
| Time to peak | ~1 h | Maximum concentration reached approximately 1 hour after oral administration on the Rybelsus and Ozempic tablet label, and 1 hour post dose on the Wegovy label; the EU product information also gives approximately 1 hour post dose1,2,3 |
| Bioavailability | 1% | Estimated absolute bioavailability of approximately 0.4% to 1% for Rybelsus 3, 7 and 14 mg and 1% to 2% for Ozempic tablets 1.5, 4 and 9 mg; 1% to 2% for Wegovy tablets; about 1% for the 3, 7 and 14 mg strengths and up to 2% for the 25 and 50 mg strengths in the EU information; 89% after subcutaneous injection (Wegovy label)1,2,3 |
| Steady state | Not in the app | Steady-state exposure after 4 to 5 weeks of once-daily tablets; approximately 77 nmol/L after the 25 mg Wegovy tablet in patients with obesity or overweight1,2 |
On the Wegovy label, 90% of patients on the 25 mg tablet had average concentrations between 27 and 186 nmol/L, against 51 to 110 nmol/L with the 2.4 mg weekly injection.2 For levothyroxine, the label reports that total thyroxine area under the curve "was increased by 33%" after a single 600 mcg levothyroxine dose given with semaglutide tablets, with maximum exposure unchanged.1
Level over 6 weeks
Level, as a share of the peak after one 100 mg dose
As studied: once daily1.
An illustration from a pharmacokinetic model using a half-life of 161 hours (6.71 days). It is not a measured level or a suggested dose.
Human studies
The table lists trials of the tablet in type 2 diabetes (PIONEER 1, PIONEER 6, SOUL) and in overweight or obesity (OASIS 1, OASIS 4), each with its own comparator, dose and estimand.
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Aroda and colleagues, PIONEER 1, Diabetes Care 20198 | Phase 3a, randomised, double-blind, placebo-controlled trial at 93 sites in nine countries | 703 adults with type 2 diabetes insufficiently controlled with diet and exercise; mean baseline HbA1c 8.0% | Oral semaglutide 3, 7 or 14 mg or placebo once daily; 26 weeks | Placebo-adjusted HbA1c difference at week 26 (treatment policy estimand) of -0.6% (3 mg), -0.9% (7 mg) and -1.1% (14 mg); body weight difference -0.1, -0.9 and -2.3 kg; trial product discontinuations 2.3% to 7.4% with oral semaglutide and 2.2% with placebo8 |
| Husain and colleagues, PIONEER 6, New England Journal of Medicine 20195 | Event-driven, randomised, double-blind, placebo-controlled cardiovascular safety trial; Novo Nordisk funded | 3183 patients at high cardiovascular risk (mean age 66 years) | Oral semaglutide (3, 7, then 14 mg) or placebo once daily; median time in trial 15.9 months | Major adverse cardiovascular events in 61 of 1591 (3.8%) against 76 of 1592 (4.8%), hazard ratio 0.79 (95% CI 0.57 to 1.11); death from any cause 23 (1.4%) against 45 (2.8%); gastrointestinal adverse events leading to discontinuation more common with oral semaglutide5 |
| McGuire and colleagues, SOUL, New England Journal of Medicine 20256 | Double-blind, placebo-controlled, event-driven superiority trial; Novo Nordisk funded | 9650 participants aged 50 or older with type 2 diabetes (HbA1c 6.5 to 10.0%) and atherosclerotic cardiovascular disease, chronic kidney disease, or both | Oral semaglutide (maximal dose 14 mg) or placebo once daily, plus standard care; median follow-up 49.5 months | Primary outcome in 579 of 4825 (12.0%) against 668 of 4825 (13.8%), hazard ratio 0.86 (95% CI 0.77 to 0.96; P = 0.006); confirmatory secondary outcomes did not differ significantly; serious adverse events 47.9% against 50.3%6 |
| Knop and colleagues, OASIS 1, Lancet 20237 | Randomised, double-blind, placebo-controlled phase 3 superiority trial at 50 clinics in nine countries; Novo Nordisk funded, and the declarations of interests list three authors as Novo Nordisk employees | 667 adults with overweight or obesity, without type 2 diabetes | Oral semaglutide escalated to 50 mg or placebo once daily, plus lifestyle intervention; 68 weeks | Weight change to week 68 of -15.1% against -2.4% (difference -12.7 percentage points, 95% CI -14.2 to -11.3); adverse events in 92% against 86%; gastrointestinal adverse events in 80% against 46%7 |
| Wharton and colleagues, OASIS 4, New England Journal of Medicine 20254 | 71-week, double-blind, randomised, placebo-controlled trial at 22 sites in four countries; Novo Nordisk funded | 307 adults without diabetes with a BMI of 30 or higher, or 27 or higher with at least one obesity-related complication | Oral semaglutide 25 mg or placebo once daily (2:1), plus lifestyle interventions; week 64 endpoints | Weight change to week 64 of -13.6% against -2.2% (estimated difference -11.4 percentage points, 95% CI -13.9 to -9.0); gastrointestinal adverse events 74.0% against 42.2%4 |
Deeper analysis: OASIS 4
Wharton and colleagues reported OASIS 4 in the New England Journal of Medicine in 2025 as a 71-week, double-blind, randomised, placebo-controlled trial at 22 sites in four countries.4 It enrolled persons without diabetes with a BMI of 30 or higher, or 27 or higher with at least one obesity-related complication, and assigned 205 to oral semaglutide 25 mg and 102 to placebo once daily, plus lifestyle interventions.4 The coprimary end points at week 64 were "the percent change in body weight and a reduction of 5% or more in body weight".4 The estimated mean change in body weight was -13.6% with oral semaglutide and -2.2% with placebo, an estimated difference of -11.4 percentage points (95% confidence interval -13.9 to -9.0).4 Secondary results: participants on oral semaglutide were "significantly more likely" than those on placebo to have body-weight reductions of 5% or more, 10% or more, 15% or more and 20% or more, and to have an improved physical function score.4 Gastrointestinal adverse events were more common with oral semaglutide than with placebo (74.0% against 42.2%).4 The registry entry lists the trial as completed and reports no deaths in either group (0 of 205 on oral semaglutide, 0 of 102 on placebo) and serious adverse events in 8 of 204 and 9 of 102.9 The Wegovy label describes the same trial as Study 7 (NCT05564117), a 64-week trial of 307 patients, and reports weight change of -13.6% against -2.4% on placebo, a placebo difference of -11.2% (95% CI -13.6 to -8.8), figures that differ slightly from the published -2.2% and -11.4 points.2 The authors' own stated limitations are not quoted here, because the PubMed record that was read carries the trial's summary and not its full text.4 Funding is stated as "Funded by Novo Nordisk", and the registry names Novo Nordisk A/S as lead sponsor and its Clinical Transparency department as study director's organisation; the author list places three authors (R.D.V., T.K. and C.S.) at Novo Nordisk entities in Søborg, Denmark and Bangalore, India.4,9
Deeper analysis: PIONEER 6
Husain and colleagues, from a group that includes the University Health Network in Toronto and Novo Nordisk, reported PIONEER 6 in the New England Journal of Medicine in 2019.5 It was an event-driven, randomised, double-blind, placebo-controlled trial in patients at high cardiovascular risk: aged 50 years or older with established cardiovascular or chronic kidney disease, or aged 60 years or older with cardiovascular risk factors only.5 The trial "was designed to rule out 80% excess cardiovascular risk as compared with placebo", with a noninferiority margin of 1.8 for the upper boundary of the 95% confidence interval of the hazard ratio.5 Of 3183 patients, major adverse cardiovascular events occurred in 61 of 1591 (3.8%) on oral semaglutide and 76 of 1592 (4.8%) on placebo (hazard ratio 0.79; 95% CI 0.57 to 1.11).5 The components were: death from cardiovascular causes 15 (0.9%) against 30 (1.9%) (hazard ratio 0.49; 95% CI 0.27 to 0.92); nonfatal myocardial infarction 37 (2.3%) against 31 (1.9%) (hazard ratio 1.18; 95% CI 0.73 to 1.90); and nonfatal stroke 12 (0.8%) against 16 (1.0%) (hazard ratio 0.74; 95% CI 0.35 to 1.57).5 Death from any cause occurred in 23 of 1591 (1.4%) against 45 of 1592 (2.8%) (hazard ratio 0.51; 95% CI 0.31 to 0.84).5 The authors conclude that "the cardiovascular risk profile of oral semaglutide was not inferior to that of placebo", and the PubMed record states that gastrointestinal adverse events leading to discontinuation "were more common with oral semaglutide".5 The registry entry lists 23 deaths among 1591 on oral semaglutide and 45 among 1591 in the comparison group (the publication gives 1592 on placebo), and serious adverse events in 301 and 358 respectively.10,5 The PubMed record read for this trial carries the summary only, so the authors' own stated limitations are not quoted here.5 The trial was "Funded by Novo Nordisk", and the affiliation list places authors M.D., O.K.J. and M.T. at Novo Nordisk in Søborg, Denmark; the registry names Novo Nordisk A/S as lead sponsor.5,10
Deeper analysis: SOUL
McGuire and colleagues reported SOUL in the New England Journal of Medicine in 2025.6 It was a double-blind, placebo-controlled, event-driven superiority trial in participants aged 50 or older with type 2 diabetes (HbA1c 6.5 to 10.0%) and known atherosclerotic cardiovascular disease, chronic kidney disease, or both, given once-daily oral semaglutide (maximal dose 14 mg) or placebo in addition to standard care.6 The primary outcome was major adverse cardiovascular events, a composite of death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke, in a time-to-first-event analysis; confirmatory secondary outcomes included major kidney disease events (a five-point composite).6 Among 9650 randomised participants (mean follow-up 47.5 months, median 49.5 months), the primary outcome occurred in 579 of 4825 (12.0%; 3.1 events per 100 person-years) on oral semaglutide and 668 of 4825 (13.8%; 3.7 per 100 person-years) on placebo, hazard ratio 0.86 (95% CI 0.77 to 0.96; P = 0.006).6 The authors report that "the results for the confirmatory secondary outcomes did not differ significantly between the two groups", a null result that includes the kidney composite.6 Serious adverse events occurred in 47.9% on oral semaglutide and 50.3% on placebo, and gastrointestinal disorders in 5.0% and 4.4%.6 The Rybelsus and Ozempic tablet label states that in this trial "safety data collection was limited to serious adverse events (including death), adverse events leading to discontinuation, and adverse events of special interest", and that study drug was permanently discontinued due to an adverse event in 15.5% on semaglutide tablets and 11.6% on placebo.1 The registry entry lists 528 deaths among 4825 on oral semaglutide and 579 among 4825 on placebo, and serious adverse events in 2312 and 2427.11 The PubMed record read for this trial carries the summary only, so the authors' own stated limitations are not quoted here.6 The trial was "Funded by Novo Nordisk", the registry names Novo Nordisk A/S as lead sponsor, and the author list places several authors (including M.D.M.E., M.S.R., G.K.H., K.B.-F., M.G. and J.-P.D.) at Novo Nordisk in Søborg, Denmark.6,11
Deeper analysis: PIONEER 1
Aroda and colleagues reported PIONEER 1 in Diabetes Care in 2019, with a treatment policy estimand ("regardless of trial product discontinuation or rescue medication use") and a trial product estimand ("on trial product without rescue medication use").8 The authors conclude that oral semaglutide showed improvements in HbA1c at all doses and body weight loss at the 14 mg dose, and report "Mild-to-moderate transient gastrointestinal events" as the most common adverse events.8 The PubMed record read for this trial does not state its funder or the authors' limitations; it lists three authors (O.K.J., E.C. and C.L.H.) at Novo Nordisk A/S in Søborg, Denmark.8
Doses reported in studies and on labels
The table lists the doses as the labels and trial records state them, with the comparator, length and number of people where the source gives them. The app lists a typical range of 1.5 to 25 mg per day.
| Source | Setting | Doses reported | Comparator, length and people |
|---|---|---|---|
| Rybelsus label1 | Adults with type 2 diabetes mellitus | 3 mg once daily for days 1 to 30 (the label says this dosage "is not effective for glycemic control"), 7 mg for days 31 to 60, then 7 mg or 14 mg from day 61 depending on whether additional glycemic control is needed | Labelled schedule; no comparator |
| Ozempic tablets label1 | Adults with type 2 diabetes mellitus | 1.5 mg once daily for days 1 to 30, 4 mg for days 31 to 60, then 4 mg or 9 mg from day 61 depending on whether additional glycemic control is needed | Labelled schedule; no comparator |
| Wegovy tablets label2 | Adults, for cardiovascular risk reduction or weight reduction | 1.5 mg once daily for days 1 to 30, 4 mg for days 31 to 60, 9 mg for days 61 to 90, and 25 mg from day 91 | Labelled schedule; no comparator |
| OASIS 49 | Adults with obesity or overweight, without type 2 diabetes | Escalation every 4 weeks through 3, 7 and 14 mg to 25 mg once daily, maintained to week 64 | Placebo; 64 weeks; 205 on oral semaglutide, 102 on placebo |
| PIONEER 610 | Adults with type 2 diabetes at high cardiovascular risk | 3 mg weeks 0 to 4, 7 mg weeks 4 to 8, 14 mg from week 9, for up to 82 weeks | Placebo; median time in trial 15.9 months; 3183 randomised |
| SOUL11 | Adults with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both | 3 mg weeks 0 to 4, 7 mg weeks 4 to 8, then 14 mg maintenance to the end of treatment (up to week 260) | Placebo; median follow-up 49.5 months; 9650 randomised |
| OASIS 17 | Adults with overweight or obesity, without type 2 diabetes | Escalated to 50 mg once daily | Placebo; 68 weeks; 667 randomised |
Side effects reported
Sources in this part
For the Rybelsus and Ozempic tablet label's pool of two placebo-controlled trials in adults with type 2 diabetes, gastrointestinal adverse reactions occurred in 41% on 14 mg, 32% on 7 mg and 21% on placebo.1 The same label states that the majority of reports of nausea, vomiting and diarrhea occurred during dose escalation, and that 8% on 14 mg and 4% on 7 mg discontinued because of gastrointestinal adverse reactions against 1% on placebo.1 The patient information on the label names nausea, stomach (abdominal) pain, diarrhea, decreased appetite, vomiting and constipation as the most common side effects.1 In the label's pool of placebo- and active-controlled trials, pancreatitis was reported as a serious adverse event in 6 patients on semaglutide tablets against 1 on comparators.1 In the Wegovy tablet trial in obesity or overweight (204 patients on the tablet), permanent discontinuation because of adverse reactions was 6.9% on the tablet and 5.9% on placebo, and 5% of tablet patients and none on placebo reported dysesthesia.2 The Rybelsus and Ozempic tablet label carries a boxed warning on thyroid C-cell tumors: "In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures", and it is unknown whether the tablets cause such tumors in humans.1 The label lists the tablets as contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.1
Bloodwork and markers
Sources in this part
The app lists blood glucose, HbA1c and body weight as markers to monitor. In PIONEER 1, HbA1c at week 26 fell against placebo by 0.6% to 1.4% depending on dose and estimand.8 The Wegovy label's dosage section states "In patients with diabetes, monitor blood glucose prior to starting and during WEGOVY treatment".2 The Rybelsus and Ozempic tablet label states that routine monitoring of serum calcitonin or thyroid ultrasound "is of uncertain value for early detection of MTC" in patients treated with the tablets.1
Regulatory and anti-doping status
The US label for Rybelsus and Ozempic tablets gives "Initial U.S. Approval: 2017" in its header.1 The label covers three Rybelsus strengths (3, 7 and 14 mg) and three Ozempic tablet strengths (1.5, 4 and 9 mg), and the Wegovy label lists tablet strengths of 1.5, 4, 9 and 25 mg.1,2 Searching the saved text of the 2026 WADA Prohibited List for "semaglutide", "GLP-1" and "incretin" returned no match.12 Section S0 of the 2026 list covers "any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use".12 A December 2025 article in Triathlon Magazine, a news source and not a regulator, states that "semaglutide is not on the Prohibited List" and that it has been on WADA's Monitoring Program since 2024.13
Storage and handling
Sources in this part
The Rybelsus and Ozempic tablet label gives storage at 20°C to 25°C (68°F to 77°F), with excursions permitted to 15°C to 30°C, in the original bottle.1
What is not known
Sources in this part
The authors' own stated limitations for OASIS 4, PIONEER 6, SOUL and PIONEER 1 are not reported here, because the PubMed records read carry the summaries and not the full texts. The Wegovy label states that the tablets "have not been studied for weight reduction in adults with type 2 diabetes and obesity or overweight".2 The Rybelsus and Ozempic tablet label states that "human relevance of thyroid C-cell tumors in rats is unknown and could not be determined by clinical studies or nonclinical studies".1 The EU product information states that within-subject variability in bioavailability could not be reliably estimated.3
Frequently asked questions
What is the half-life of oral semaglutide?
The Rybelsus and Ozempic tablet label gives the elimination half-life of semaglutide as approximately one week, and the app lists about 6.7 days (161 hours).1 The Rybelsus and Ozempic tablet label adds that semaglutide is present in the circulation for about five weeks after the last tablet dose, and the Wegovy label gives about 5 to 7 weeks after the last oral dose of 25 mg.1,2
How long does oral semaglutide take to reach its peak level?
What is the bioavailability of oral semaglutide?
Is oral semaglutide banned by WADA?
Oral semaglutide is not named in the text of the WADA 2026 Prohibited List that was searched, and a December 2025 news article states that semaglutide "is not on the Prohibited List" and has been on WADA's Monitoring Program since 2024.12,13 The same article is a news source, not the regulator, and says its status continues to be evaluated.13
What is SNAC in oral semaglutide?
What did the OASIS 4 trial find for oral semaglutide 25 mg?
What did the SOUL trial find for cardiovascular outcomes?
The primary composite of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke occurred in 579 of 4825 (12.0%) on oral semaglutide and 668 of 4825 (13.8%) on placebo, hazard ratio 0.86 (95% CI 0.77 to 0.96), in adults with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both.6 The confirmatory secondary outcomes did not differ significantly between the groups.6
Guides, tools and comparisons
- Oral semaglutide dosageA guide that answers a question on this compound.
- Oral semaglutide vs orforglipronA side-by-side with another compound.
- Previous in GLP-1 and incretin: LiraglutideThe compound before this one in the class.
- Next in GLP-1 and incretin: OrforglipronThe compound after this one in the class.
References
- Novo Nordisk. Rybelsus (semaglutide) tablets and Ozempic (semaglutide) tablets, for oral use. US prescribing information, DailyMed record, version 14, 2026. DailyMed label (Rybelsus and Ozempic tablets)
- Novo Nordisk. Wegovy (semaglutide) injection and tablets. US prescribing information, DailyMed record, version 19, 2026. DailyMed label (Wegovy)
- European Medicines Agency. Rybelsus: summary of product characteristics (EPAR product information). EMA product information
- Wharton S, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. N Engl J Med 2025;393(11):1077-1087. PMID 40934115
- Husain M, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2019;381(9):841-851. PMID 31185157
- McGuire DK, et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med 2025;392(20):2001-2012. PMID 40162642
- Knop FK, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023;402(10403):705-719. PMID 37385278
- Aroda VR, et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care 2019;42(9):1724-1732. PMID 31186300
- ClinicalTrials.gov. NCT05564117 (OASIS 4). Registry entry with posted results. NCT05564117
- ClinicalTrials.gov. NCT02692716 (PIONEER 6). Registry entry with posted results. NCT02692716
- ClinicalTrials.gov. NCT03914326 (SOUL). Registry entry with posted results. NCT03914326
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list
- Cooper B. What Athletes Need to Know About the 2026 WADA Prohibited List and the Status of Semaglutide (Ozempic). Triathlon Magazine, 3 December 2025. Triathlon Magazine article